

and hematoma internal membrane removal are the risk factors of unfavorable outcome in patients ≥ 75 years old.

<http://dx.doi.org/10.1016/j.pbj.2017.07.149>

PS103

The frequency of MINS (Myocardial Injury after Noncardiac Surgery) and others postoperative complications in different age groups of elderly patients who underwent endovascular aortic repair because of abdominal aortic aneurysm

Gajdosz Anna*, Kaszuba Aleksandra

Student Scientific Society at the Second Department of Internal Diseases UJ CM, Poland

E-mail address: anna.gajdosz13@gmail.com

(G. Anna).



Aim: The aim of our study was to estimate frequency of MINS and others complications after endovascular aorta repair because of AAA in different age groups.

Introduction: Nowadays, endovascular aneurysm repair (EVAR) is the most common technique for repair of abdominal aorta aneurysm (AAA). This procedure involves less complications than open surgery, nevertheless they still occurs.

Methods: The study group consisted of 143 patients (85.3% men), aged 76.8 ± 7.7 with AAA who had endovascular aneurysm repair between January 2015 and May 2017 in the Department of Vascular Surgery and Angiology. Patients were divided into two groups depending on age: group I ≤ 75 years (60 patients, aged 69.3 ± 4.5), group II > 75 yrs (83 patients, aged 82.2 ± 4.2). We considered coexistent diseases, some laboratory tests and Revised Cardiac Risk Index for Pre-Operative Risk (Lee index). Statistical analysis was performed with U Mann-Whitney and Chi2 tests.

Results: The study groups were comparable regarding the coexistent diseases and preoperative risk. Older patients had higher mean creatine level on admission than younger patients (group I: 103.29 ± 84.10 vs. group II: 118.5 ± 61.9 $\mu\text{mol/l}$, $p < 0.005$) and lower eGFR (80.6 ± 27.6 vs. 61.61 ± 21.9 vs. 1.73 ml/min/m^2 , $p < 0.001$). The mean concentration of haemoglobin and amount of white blood cells were also lower in elderly patient (13.19 ± 1.93 vs. 12.9 ± 18.3 g/dl , $p = 0.01$; 8.23 ± 2.74 vs. $7.49 \pm 2.7 \times 103/\mu\text{l}$, $p = 0.04$).

Frequency of some complications such as acute kidney injury, pneumonia, sepsis, stroke or intrahospital mortality were similar in both groups.

However, we observed a statistically significant difference in the frequency of MINS (26.67% vs. 45.78%; $p = 0.04$). Older patients also needed red blood cells concentrate transfusion after surgery more often than younger (6.67% vs. 19.28%; $p = 0.03$).

Conclusion: MINS is the most common complication after EVAR. Age seems to be a significant feature which increases the frequency of MINS in compared groups despite similar coexistent diseases and preoperative risk assessment determined by Lee index.¹⁻³

References

1. Sessler DI, Devereaux PJ. Perioperative troponin screening. *Anesth Analg*. 2016;123:359–60.
2. Devereaux PJ, Sessler DI. Cardiac complications in patients undergoing major noncardiac surgery. *N Engl J Med*. 2015;373:2258–69.
3. Jennifer A, Heller, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? *J Vasc Surg*. 2000;32:1091–100.

<http://dx.doi.org/10.1016/j.pbj.2017.07.150>

PS210

Evaluation of clinical characteristics as indicators for shunt procedure in patients with medulloblastoma



A. Paunović*, F. Milisavljević, J. Bošković

School of Medicine, University of Belgrade, Serbia

E-mail address: aleksandra.paunovic92@gmail.com

(A. Paunović).

Aim: Determining clinical characteristics and parameters reliable as predictors of the need for the shunt installation and their relation to the treatment outcome.

Introduction: Medulloblastoma represents the most common pediatric tumor, that most frequently involves posterior cranial fossa and often manifests as hydrocephalus. Current therapy involves tumor excision and posterior cranial fossa decompression, with or without temporary external drainage of cerebrospinal fluid, endoscopic ventriculocisternostomy and ventriculoperitoneal (VP) shunt placement.

Methods: This retrospective study included 36 patients treated in the period from January 1st 2007 to December 31st 2015 in the Clinic of Neurosurgery, Clinical Center of Serbia. Basic demographic data, symptoms and signs at admission, degree of tumor resection and disease outcome information were analyzed.

Results: 22 patients (61.1%) were male and 14 (38.9%) were female, most of them 4–14 years old (58.3). Sex and age showed no significant correlation with VP shunt installation, or timing of shunt installation. VP shunt was installed in 92% of patients, in 33.3% prior to and in remaining after surgery. The most frequently observed symptoms on admission were cerebellar symptomatology (91.2%), headache (75.7%) and vomiting (68.5%), which showed no significant correlation with the VP shunt installation and shunt installation timing. In 83% of patients total resection was achieved. The degree of tumor resectability and VP shunt installation were significantly related ($p < 0.001$). Correlation among shunt installation and treatment outcomes, as well as the shunt installation timing and outcome showed a statistical significance ($p < 0.001$).

Conclusion: No clinical characteristics reliable as prognostic parameter for VP shunt installation in medulloblastoma patients have been found. Shunt placement is recommended in all cases of incomplete tumor resection, unless already placed preoperatively. Patients with a shunt placed prior to surgery have had significantly better outcome.¹⁻³⁵

References

1. Lachi PK, Syed FAJD, Moinca I, et al. Medulloblastoma: a common pediatric tumor: prognostic factors and predictors of outcome. *Asian J Neurosurg*. 2015;10:50.
2. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. *Radiographics*. 2003;23:1613–37.
3. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathol*. 2012;123:465–72.
4. David NL, Arie P, Guido R, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. 2016;131:803–20.
5. Albright AL, Pollack IF, Adelson PD. Principles and practice of pediatric neurosurgery. 3rd ed. New York: Thieme; 2014.
6. Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncol*. 2016;17:484–95.
7. Nikitovic MR, Golubicic IV, Borojevic ND, et al. Pediatric brain tumors-diagnosis and treatment. *Acta Chir Jugosl*. 2009;56:19–24.
8. Nikitovic MR, Golubicic IV. Treatment options for childhood medulloblastoma. *Vojnosanit Pregl*. 2013;70:773–7.
9. Fatema M, Ira JD. Treatment approach for recurrent medulloblastoma. *Clin Insights: Opt Therapy Pediatr Medulloblastoma*. 2015:59–73.
10. Pilkington G, Walker D. Guidelines on the diagnosis and management of Adult PNETs. *Br Neuro-Oncol Soc/NCAT Rare Tumour Guidelines*. 2011.

11. Handler MH, Callahan B. Laparoscopic placement of distal ventriculoperitoneal shunt catheters. *J Neurosurg Pediatr.* 2008;2:282–5.
12. Naftel RP, Argo JL, Shannon CN, et al. Laparoscopic versus open insertion of the peritoneal catheter in ventriculoperitoneal shunt placement: review of 810 consecutive cases. *J Neurosurg.* 2011;115:151–8.
13. Roth J, Sagie B, Szold A, Elran H. Laparoscopic versus non-laparoscopic-assisted ventriculoperitoneal shunt placement in adults. A retrospective analysis. *Surg Neurol.* 2007;68:177–85.
14. Pettersson D, Schmitz KR, Jeffrey M, et al. Medulloblastoma: seeding of VP shunt tract and peritoneum. *Clin Pract.* 2012;2:e37.
15. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet.* 1975;7905:480–4.
16. Culley DJ, Berger MS, Shaw D, et al. An analysis of factors determining the need for ventriculoperitoneal shunts after posterior fossa tumor surgery in children. *Neurosurgery.* 1994;34:402–7 [discussion 407–8].
17. Riva-Cambrin J, Detsky AS, Lamberti-Pasculli M, et al. Predicting postresection hydrocephalus in pediatric patients with posterior fossa tumors. *J Neurosurg Pediatr.* 2009;3:378–85.
18. Albright L, Reigel DH. Management of hydrocephalus secondary to posterior fossa tumors. *J Neurosurg.* 1977;46:52–5.
19. Raimondi AJ, Tomita T. Hydrocephalus and infratentorial tumors. Incidence, clinical picture and treatment. *J Neurosurg.* 1981;55:174–82.
20. Hekmatpanah J, Mullan S. Ventriculo-caval shunt in the management of posterior fossa tumors. *J Neurosurg.* 1967;26:609–13.
21. Schneider C, Ramaswamy V, Kulkarni AV, et al. Clinical implication of medulloblastoma subgroups: incidence of CSF diversion surgery. *J Neurosurg Pediatr.* 2014;1–7.
22. Foreman P, McClugage S, Naftel R, et al. Validation and modification of a predictive model of postresection hydrocephalus in pediatric patients with posterior fossa tumors. *J Neurosurg Pediatr.* 2013;12:220–6.
23. Morelli D, Pirotte B, Lubansu A, et al. Persistent hydrocephalus after early surgical management of posterior fossa tumors in children: is routine preoperative endoscopic third ventriculostomy justified? *J Neurosurg.* 2005;103:247–52.
24. Gnanalingham KK, Lafuente J, Thompson D, et al. The natural history of ventriculomegaly and tonsillar herniation in children with posterior fossa tumours—an MRI study. *Pediatr Neurosurg.* 2003;39:246–53.
25. Sainte-Rose C, Cinalli G, Roux FE, et al. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. *J Neurosurg.* 2001;95:791–7.
26. Tamburrini G, Pettorini BL, Massimi L, et al. Endoscopic third ventriculostomy: the best option in the treatment of persistent hydrocephalus after posterior cranial fossa tumour removal? *Childs Nerv Syst.* 2008;24:1405–12.
27. Tuli S, Tuli J, Drake J, et al. Predictors of death in pediatric patients requiring cerebrospinal fluid shunts. *J Neurosurg.* 2004;100:442–6.
28. Drake JM, Kestle JRW, Milner R, et al. Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus. *Neurosurgery.* 1998;43:294.
29. Cochrane DD, Kestle JRW. The influence of surgical operative experience on the duration of first ventriculoperitoneal shunt function and infection. *Pediatr Neurosurg.* 2003;38:295–301.
30. McLaurin RL. Disadvantages of the preoperative shunt in posterior fossa tumors. *Clin Neurosurg.* 1983;30:286–92.
31. Taylor WA, Todd NV, Leighton SE. CSF drainage in patients with posterior fossa tumours. *Acta Neurochir (Wien).* 1992;117:1–6.
32. Di Rocco F, Juca CE, Zerah M, et al. Endoscopic third ventriculostomy and posterior fossa tumors. *WNEU.* 2013;79:S18.e15–9.
33. Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy. *J Neurosurg Pediatr.* 2011;7:643–9.
34. Kulkarni AV, Drake JM, Mallucci CL, et al. Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus. *J Pediatr.* 2009;155:254–9.
35. Drake JM. Canadian Pediatric Neurosurgery Study Group. Endoscopic third ventriculostomy in pediatric patients: the Canadian experience. *Neurosurgery.* 2007;60:881–6.

<http://dx.doi.org/10.1016/j.pbj.2017.07.151>

PS009

Percutaneous cholecystostomy in the management of acute cholecystitis

Sara Gomes-Rodrigues^{1,*}, Telma Vale-Fonseca^{1,2}, Rui Mendes Costa^{1,2}

¹ Faculty of Medicine of University of Porto, Porto, Portugal

² Department of General Surgery. Hospital of São João, Porto, Portugal

E-mail address: sara.gomes.rodrigues@gmail.com (S. Gomes-Rodrigues).



Aim: The aim of this study is to clarify the role of percutaneous cholecystostomy in calculous acute cholecystitis treatment and to elucidate about its association with the surgical treatment.

Introduction: Laparoscopic cholecystectomy is the gold-standard treatment in acute cholecystitis. However, percutaneous cholecystostomy stands as an alternative therapeutic approach among the elderly or patients with several comorbidities.

Methods: In December 2016, a systematic database search on PubMed, Scopus and Web of Science was conducted to identify articles on percutaneous cholecystostomy published from January 2013 to November 2016, using the query “(acute cholecystitis OR severe cholecystitis) AND (cholecystostomy OR percutaneous cholecystostomy OR cholecystostomy tube)”. In total, 290 articles were found and submitted to inclusion and exclusion criteria.

Results: A total of 13 records involving 1130 patients from 10 different countries met all inclusion criteria and were therefore included in this systematic review. All studies found eligible concluded percutaneous cholecystostomy is a potentially safe and effective therapeutic approach among high-risk surgical patients in the setting of acute cholecystitis. Percentage of patients undergoing percutaneous cholecystostomy followed by cholecystectomy varied between 7.2% and a maximum of 66.7%, with a conversion rate fluctuating between 0.0% and 66.7%. Complication and mortality rates ranged from 2.2% to 41.7% and 0.0% and 43.2%, respectively.

Conclusion: Percutaneous cholecystostomy is generally considered safe and effective among high-risk surgical patients diagnosed with acute cholecystitis.^{1,2}

References

1. Popowicz A, Lundell L, Gerber P, et al. Cholecystostomy as bridge to surgery and as definitive treatment or acute cholecystectomy in patients with acute cholecystitis. *Gastroenterol Res Pract.* 2016;2016.
2. Jung W, Park D. Timing of cholecystectomy after percutaneous cholecystostomy for acute cholecystitis. *Korean J Gastroenterol.* 2015;66:209–14.

<http://dx.doi.org/10.1016/j.pbj.2017.07.152>

PS092

The influence of maternal age and parity on perinatal outcomes – A preliminary study

B. Adrianowicz

Perinatology Students' Scientific Group, Department of Obstetrics and Perinatology, Jagiellonian University Medical College, Poland
E-mail address: beaadrr@gmail.com.



Aim: The aim of the study was to compare maternal, perinatal and neonatal outcomes depending on maternal age and parity.

Introduction: Advanced maternal age at childbirth has been associated with adverse perinatal and neonatal outcomes. As mean maternal age in developed countries is increasing decade by decade, the issue of perinatal outcomes among older patients seems to be of utmost importance.

Methods: It is a preliminary study that enrolled 243 women who gave birth in the Department of Obstetrics and Perinatology of the University Hospital in Kraków, Poland, during a one-month period (in May 2017). The patients were divided into 2 groups: >30 and ≤30 years old. The two groups were subsequently subdivided into 4 subgroups. Maternal, perinatal and neonatal outcomes were compared between all the subgroups.

Results: Comparison of women at age >30 and ≤30 revealed that advanced maternal age may constitute a predisposing factor for stillbirth, preterm delivery and congenital disorders. At the same time, the patients in the first group were at lower risk of SGA (small for gestational age) and LGA (large for gestational age)